Shares of Novavax, Inc. (NASDAQ:NVAX – Get Rating) hit a new 52-week low during mid-day trading on Monday . The stock traded as low as $27.96 and last traded at $28.01, with a volume of 15394 shares. The stock had previously closed at $30.41.
Wall Street Analysts Forecast Growth
NVAX has been the subject of several research analyst reports. Cowen dropped their price target on Novavax from $150.00 to $110.00 and set an “outperform” rating for the company in a research note on Tuesday, August 9th. Cantor Fitzgerald boosted their target price on Novavax from $146.00 to $168.00 in a research note on Wednesday, June 8th. Cowen reduced their price target on Novavax to $110.00 in a report on Monday, August 15th. Finally, B. Riley reduced their price target on Novavax from $181.00 to $171.00 in a report on Friday, July 22nd. One research analyst has rated the stock with a sell rating, two have issued a hold rating and five have given a buy rating to the company. Based on data from MarketBeat.com, Novavax has a consensus rating of “Moderate Buy” and a consensus price target of $151.00.
Novavax Trading Down 3.4 %
The company has a market cap of $2.15 billion, a PE ratio of -1.41, a P/E/G ratio of 0.11 and a beta of 1.65. The firm has a 50 day moving average of $43.36 and a two-hundred day moving average of $53.12.
Hedge Funds Weigh In On Novavax
Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. San Luis Wealth Advisors LLC bought a new position in Novavax in the 1st quarter valued at approximately $29,000. Rockefeller Capital Management L.P. lifted its position in Novavax by 62.9% in the 4th quarter. Rockefeller Capital Management L.P. now owns 386 shares of the biopharmaceutical company’s stock valued at $55,000 after acquiring an additional 149 shares in the last quarter. Mascoma Wealth Management LLC bought a new position in shares of Novavax during the 2nd quarter valued at $27,000. Focused Wealth Management Inc bought a new position in shares of Novavax during the 1st quarter valued at $45,000. Finally, Dixon Hughes Goodman Wealth Advisors LLC bought a new position in shares of Novavax during the 1st quarter valued at $53,000. 42.63% of the stock is owned by institutional investors.
Novavax, Inc, a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company's vaccine candidates include NVX-CoV2373, a coronavirus vaccine candidate that is in two Phase III trials, one Phase IIb trial, and one Phase I/II trial; NanoFlu, a nanoparticle seasonal quadrivalent influenza vaccine candidate that is in Phase 3 clinical trial; and ResVax, a respiratory syncytial virus (RSV) fusion (F) protein nanoparticle vaccine candidate.
- Get a free copy of the StockNews.com research report on Novavax (NVAX)
- 3 Airline Stocks Stuck in a Holding Pattern
- Roku Stock is Down but Not Out
- Is Ford Rolling To A Rebound After Its Q3 Warning
- If You’re Hungry for Value, Take a Bite on Ruth’s Hospitality Grp
- Has AMD stock stock fallen too far?
Receive News & Ratings for Novavax Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novavax and related companies with MarketBeat.com's FREE daily email newsletter.